Sickle Cell Disease – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of sickle cell disease (SCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets in North America and Europe (the United States, France, Germany, Italy, Spain, and the United Kingdom). We report the diagnosed prevalence of SCD for each country, as well as annualized case counts projected to the national population.
The patient populations are forecast over a period of 10 years for the mature pharmaceutical markets of the United States and Europe.
Clarivate Epidemiology’s SCD forecast will answer the following questions:
- Of all people diagnosed with SCD, how many in each of the pharmaceutical markets under study are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SCD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following SCD patient populations:
- Diagnosed prevalent cases of SCD.
- Diagnosed prevalent cases by disease subtype.
- Diagnosed prevalent cases by treatment status.
Note: Coverage may vary by country.
